Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Daiichi Sankyo
Teva
Mallinckrodt
Dow
Merck
Farmers Insurance
Accenture
Deloitte
Citi

Generated: February 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,900,638

« Back to Dashboard

Which drugs does patent 8,900,638 protect, and when does it expire?

Patent 8,900,638 protects KAZANO and is included in one NDA.

This patent has twenty-nine patent family members in twenty-three countries.
Summary for Patent: 8,900,638
Title:Solid preparation comprising alogliptin and metformin hydrochloride
Abstract: The present invention provides a solid preparation containing compound (I) [compound (I) is as defined in the specification] or a salt thereof, and metformin hydrochloride, which is useful as a therapeutic drug for diabetes and the like, and superior in the preservation stability. A solid preparation having a first part and a second part: a first part: a part containing compound (I) or a salt thereof and substantially free of metformin hydrochloride a second part: a part containing metformin hydrochloride and substantially free of compound (I) and a salt thereof.
Inventor(s): Yamamoto; Kazumichi (Osaka, JP), Koyama; Hiroyoshi (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:12/452,705
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Formulation; Use;

Drugs Protected by US Patent 8,900,638

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa KAZANO alogliptin benzoate; metformin hydrochloride TABLET;ORAL 203414-002 Jan 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Takeda Pharms Usa KAZANO alogliptin benzoate; metformin hydrochloride TABLET;ORAL 203414-001 Jan 25, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,900,638

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2007-188574Jul 19, 2007
PCT Information
PCT FiledJuly 16, 2008PCT Application Number:PCT/JP2008/063228
PCT Publication Date:January 22, 2009PCT Publication Number: WO2009/011451

International Patents Family Members for US Patent 8,900,638

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 067557 ➤ Try a Free Trial
Australia 2008276842 ➤ Try a Free Trial
Brazil PI0814299 ➤ Try a Free Trial
Canada 2694620 ➤ Try a Free Trial
China 101801351 ➤ Try a Free Trial
Colombia 6160301 ➤ Try a Free Trial
Costa Rica 11267 ➤ Try a Free Trial
Dominican Republic P2010000028 ➤ Try a Free Trial
Eurasian Patent Organization 020870 ➤ Try a Free Trial
Eurasian Patent Organization 201070164 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Cerilliant
Mallinckrodt
Julphar
US Department of Justice
Baxter
Covington
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot